Share on StockTwits

Genocea Biosciences’ (NASDAQ:GNCA) lock-up period is set to expire on Monday, August 4th. Genocea Biosciences had issued 5,500,000 shares in its initial public offering on February 5th, Analyst Ratings.Net reports. The total size of the offering was $66,000,000 based on an initial share price of $12.00. After the end of Genocea Biosciences’ lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Shares of Genocea Biosciences (NASDAQ:GNCA) traded down 2.24% on Friday, hitting $17.02. The stock had a trading volume of 7,409 shares. Genocea Biosciences has a 52-week low of $10.90 and a 52-week high of $23.99. The stock has a 50-day moving average of $17.55 and a 200-day moving average of $17.34. The company’s market cap is $294.9 million.

Genocea Biosciences (NASDAQ:GNCA) last released its earnings data on Tuesday, May 6th. The company reported ($0.76) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.52) by $0.24. Analysts expect that Genocea Biosciences will post $-2.07 EPS for the current fiscal year.

Genocea Biosciences, Inc is a United States-based clinical-stage company that develops T cell vaccines.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.